secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImageneBio, Inc. (IMA)
CIK:        0001835579
Form:       8-K/A
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0001193125-25-179093
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImageneBio files Inmagene pre-merger financials: $13.7M loss, going concern, $6M cash
--------------------------------------------------------------------------------

- Inmagene net loss of $7.6M in Q2 2025 and $13.7M in first half 2025; accumulated deficit $197.5M.
- Cash and equivalents $6.0M at June 30, 2025; operating cash burn $19.1M in first half 2025.
- Management states substantial doubt about continuing as a going concern; cash insufficient for next 12 months.
- Term loan of $22.9M (6% interest, secured by IMG-007) automatically forgiven upon merger close July 25, 2025.
- Ikena concurrent financing of $75M contributed to fund IMG-007 development after merger.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835579/000119312525179093/0001193125-25-179093-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835579/000119312525179093/d655327d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-179093

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer